39 completed, 9 recruiting, 7 terminated, 6 unknown. 64 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 64 | Completed 39, Recruiting 9, Terminated 7, Unknown 6, Active not recruiting 3 |
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Terminated 1 |
Follow Dacarbazine: new trials by email Literature Review of Dacarbazine trials Research Report on Dacarbazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV | Phase 2 / Phase 3 | Recruiting | Linnaeus Therapeutics, Inc. | 135 | 2025-08-06 | 2026-04-22 |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant, Mucosal Melanoma | Phase 3 | Recruiting | Immatics US, Inc. | 450 | 2025-01-14 | 2026-10-30 |
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin - Classical Hodgkin Lymphoma, Child | Phase 2 / Phase 3 | Recruiting | Children's Cancer Group, China | 96 | 2024-09-25 | 2026-03-19 |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) Naporafenib, Dacarbazine, Temozolomide - Advanced or Metastatic NRAS-mutant Melanoma | Phase 3 | Active not recruiting | Erasca, Inc. | 78 | 2024-04-29 | 2026-02-27 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Active not recruiting | IDEAYA Biosciences | 420 | 2023-10-31 | 2026-02-17 |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin - Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1875 | 2023-05-11 | 2026-10-29 |
| A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) Unesbulin, Dacarbazine, Placebo - Leiomyosarcoma | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 359 | 2022-05-23 | 2025-06-13 |
| Brentuximab Vedotin in Early Stage Hodgkin Lymphoma Involved site radiotherapy, Doxorubicin, Bleomycin - Hodgkin Lymphoma | Phase 3 | Recruiting | University College, London | 1042 | 2022-04-14 | 2026-07-08 |
| First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) Doxorubicin, Bleomycin, Vinblastine - Hodgkin Lymphoma, Adult | Phase 3 | Recruiting | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | 300 | 2020-02-01 | 2024-09-27 |
| High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Vincristine, Carboplatin, Etoposide - High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 800 | 2019-11-05 | 2025-06-26 |
| Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 994 | 2019-08-29 | 2026-10-22 |
| Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator - Non-metastatic Soft-tissue Sarcoma, Resectable | Phase 3 | Recruiting | Institut Bergonié | 351 | 2019-02-14 | 2025-10-02 |
| A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W - Metastatic Melanoma, Unresectable Melanoma | Phase 3 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 256 | 2018-02-02 | 2024-09-19 |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) AL3818, Dacarbazine, AL3818 or placebo - Alveolar Soft Part Sarcoma, Leiomyosarcoma | Phase 3 | Recruiting | Advenchen Laboratories, LLC | 325 | 2017-08-15 | 2026-02-25 |
| FIL Study on ABVD DD-DI as Upfront Therapy in HL. Doxorubicin, Bleomycin, Vinblastine - Hodgkin Lymphoma | Phase 3 | Completed | Fondazione Italiana Linfomi - ETS | 500 | 2017-08-01 | 2025-08-08 |
| HD21 for Advanced Stages Bleomycin, Etoposide, Doxorubicin - Classical Hodgkin Lymphoma | Phase 3 | Unknown | University of Cologne | 1500 | 2016-07-01 | 2024-05-13 |
| A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine Ipilimumab, Dacarbazine - Melanoma | Phase 3 | Completed | Bristol-Myers Squibb | 182 | 2015-10-31 | 2020-05-19 |
| Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents cyclophosphamide, vincristine, prednisone, dacarbazine, cyclo, vcr, pred, dacarb,etop and doxo - Classical Hodgkin Lymphoma | Phase 3 | Completed | University of Giessen | 2921 | 2015-10-01 | 2026-03-31 |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec - Cutaneous Melanoma | Phase 3 | Terminated | Provectus Biopharmaceuticals, Inc. | 20 | 2015-04-01 | 2022-01-19 |
| Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) 75mg selumetinib, placebo, Dacarbazine - Metastatic, Uveal Melanoma | Phase 3 | Completed | AstraZeneca | 152 | 2014-04-01 | 2017-01-05 |
Showing 20 of 64. Sign in to see all of them.
Melanoma (27) · Hodgkin Disease (20) · Lymphoma (9) · Leiomyosarcoma (4) · Neoplasm Metastasis (4) · Skin Neoplasms (4) · Sarcoma (3) · Neoplasms (2) · Neuroblastoma (2) · Uveal Melanoma (2) · Liposarcoma (1) · Melanoma, Cutaneous Malignant (1) · Recurrence (1) · Sarcoma, Alveolar Soft Part (1) · Sarcoma, Synovial (1)
University of Cologne (5) · Bristol-Myers Squibb (4) · National Cancer Institute (NCI) (3) · AstraZeneca (2) · Eastern Cooperative Oncology Group (2) · Fondazione Michelangelo (2) · Genta Incorporated (2) · M.D. Anderson Cancer Center (2) · SWOG Cancer Research Network (2) · University College, London (2) · Vical (2) · AB Science (1) · Advenchen Laboratories, LLC (1) · American Regent, Inc. (1) · American Scitech International (1)
United States (35) · Germany (25) · Italy (24) · France (23) · United Kingdom (23) · Canada (22) · Spain (21) · Australia (18) · Netherlands (17) · Belgium (12) · Poland (12) · Israel (11) · Switzerland (11) · Czechia (10) · Russia (8)
Alessandro M Gianni, MD (2) · Andreas Engert, Prof. (2) · Dieter Koerholz, MD (2) · Frank Berthold, MD (2) · Lawrence E. Flaherty, MD (2) · Michael B. Atkins, MD (2) · Ralph M. Meyer, MD, FRCPC (2) · Sandra J. Horning, MD (2) · Volker Diehl, Prof. (2) · Agop Y. Bedikian, MD (1) · Alberto S. Pappo, MD (1) · Alex F Herrera (1) · Anas Younes, MD (1) · Anna Sureda (1)
PMID 40135712, PMID 24121121, PMID 37505794, PMID 23509310, PMID 30010775, PMID 39058968, PMID 41074963, PMID 11464889, PMID 12101494, PMID 12932669, PMID 15837968, PMID 16314615, PMID 17846017, PMID 19001327, PMID 19430405, PMID 20713848, PMID 20818855, PMID 21600759, PMID 21639808, PMID 21639810, PMID 21774708, PMID 22149921, PMID 22256804, PMID 23182987, PMID 23295794, PMID 23356491, PMID 23386127, PMID 23402397, PMID 23457002, PMID 24239220, PMID 24408395, PMID 24508103, PMID 24769640, PMID 24983357, PMID 25332243, PMID 25399552, PMID 25667295, PMID 25713437, PMID 25795410, PMID 25884515, PMID 25897153, PMID 25964643, PMID 26040620, PMID 26059332, PMID 26351345, PMID 26371143, PMID 26446943, PMID 26834240, PMID 27114593, PMID 27332902
2009 (2), U10CA032102 (2), 2004 (1), 2014 (1), 2018 (1), 2019 (1), 2023 (1), P30CA016672 (1), U10CA021115 (1), U10CA180886 (1), U10CA180888 (1)